Omeros Corp (OMER) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001285819

Market Cap 956.50 Mn

P/E 10.81

P/S 13.92

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 52.81 Mn

Add ratio to table...

About

Omeros Corporation is an innovative commercial stage biotechnology company that discovers and develops first in class protein and small molecule therapeutics for large market and orphan indications. The company concentrates its research on complement mediated diseases, cancers, and addictive or compulsive disorders. Its approved product YARTEMLEA (narsoplimab-wuug) is the first and only therapy for hematopoietic stem cell transplant associated TA TMA, acting as a selective inhibitor of mannose binding lectin associated serine protease 2. Beyond...

Omeros Corporation is an innovative commercial stage biotechnology company that discovers and develops first in class protein and small molecule therapeutics for large market and orphan indications. The company concentrates its research on complement mediated diseases, cancers, and addictive or compulsive disorders. Its approved product YARTEMLEA (narsoplimab-wuug) is the first and only therapy for hematopoietic stem cell transplant associated TA TMA, acting as a selective inhibitor of mannose binding lectin associated serine protease 2. Beyond YARTEMLEA, Omeros maintains a deep pipeline that includes product candidates such as Narsoplimab for acute respiratory distress syndrome, OMS1029 a long acting MASP 2 antibody, OMS527 a PDE7 inhibitor for cocaine use disorder and levodopa induced dyskinesia, preclinical programs in MASP 2 and MASP 3 small molecule inhibitors, OncotoX AML for acute myeloid leukemia, and the T CAT platform targeting multidrug resistant organisms. The company operates worldwide research and development activities, retains global commercial rights to YARTEMLEA, and leverages a proprietary intellectual property portfolio with patents extending to the mid 2040s.

Revenue is generated principally from product sales of YARTEMLEA in the United States, where commercial distribution began in January 2026. A major source of non-product revenue is the collaboration with Novo Nordisk, which provided an upfront cash payment of $240 million for exclusive global rights to develop and commercialize the Zaltenibart (OMS906) program. Under this agreement Omeros is eligible to receive up to $510 million in development milestone payments and up to $1.3 billion in sales based milestone payments, plus tiered royalties on net sales ranging from the high single digits to the high teens. Additional potential income stems from licensing arrangements, such as the agreement with Daiichi Sankyo that offers up to $33.5 million in milestone payments and low single digit royalties on future PDE7 inhibitor sales. The company also retains rights to its MASP 3 small molecule program and other early stage assets, which could generate future partnership or licensing revenue.

• no_segments_reported.

Omeros occupies a leading niche in the complement therapeutics arena as the sole approved treatment for TA TMA, a condition with significant unmet need. While YARTEMLEA faces potential competition from off label use of C5 inhibitors such as Soliris (eculizumab) and Ultomiris (ravulizumab), it differentiates itself by lacking a boxed warning and a REMS requirement and by not requiring pre treatment vaccinations. The broader complement inhibitor market includes agents like Empaveli (pegcetacoplan), Tavneos (avocopan), PiaSky (crovalimab), Voydeya (danicopan), and Fabhalta (iptacopan), against which Omeros emphasizes its lectin pathway focus and proprietary molecule. The company’s pipeline extends its competitive reach into areas such as acute respiratory distress syndrome, cocaine use disorder, leukemia and infectious disease, providing multiple avenues for growth beyond the current product. Omeros's long standing expertise in complement science and its extensive patent estate, with expirations reaching as late as 2046 for certain assets, reinforce its defensible position in the industry.

The company’s customers are primarily hospitals and transplant centers in the United States, where it engages directly with physicians, nurses, pharmacy teams and reimbursement departments to drive adoption of YARTEMLEA. There are approximately 175 stem cell transplant centers nationwide, with the top 80 facilities accounting for roughly eighty percent of transplant procedures, forming the core focus of its commercial efforts. To support access, Omeros offers the YARTEMLEAssist patient support program, which provides assistance to uninsured or under insured individuals undergoing transplant therapy. While the current commercial footprint is domestic, the company is evaluating partnership structures for potential ex US distribution of YARTEMLEA and future approved products.

Investment thesis

Bull case

Omeros’s strategic transaction with Novo Nordisk, which delivers an upfront $240 million and up to $2.1 billion in milestones and royalties, dramatically strengthens the company’s balance sheet and provides the working capital needed for a global launch of Yartemlia. This injection of cash, coupled with the debt repayment plan that eliminates the $25 million liquidity covenant, positions Omeros to fund the anticipated launch, scale manufacturing, and accelerate other pipeline programs without the need for additional equity or high‑cost debt. The transaction also signals external validation of Omeros’s science by a pharmaceutical leader, which may ease future licensing or partnership negotiations for other assets, creating additional revenue streams beyond the core complement franchise.
Yartemlia’s first‑in‑class status as the only approved therapy for transplant‑associated thrombotic microangiopathy (TA‑TMA) creates a sizable, underserved market. With up to 56 % of allogeneic transplant recipients at risk, the patient population is large and high‑severity, generating strong pricing leverage at $36 k per vial and an expected 8–10 vial course. The company’s early adoption by transplant centers, the rapid commercial shipments reported in early January, and the supportive payor infrastructure (ICD‑10 code, CPT code, NTAP) suggest a swift reimbursement trajectory and the potential for rapid market penetration, especially in the United States where the therapeutic need is acute.
The company’s pipeline breadth mitigates the risk of overreliance on Yartemlia. Phase II‑ready OMS 1029 offers a once‑quarterly MASP‑2 antibody that could extend the company’s reach into chronic complement indications, while the MASP‑3 small‑molecule program—unrestricted by the Novo deal—provides an alternative route to the emerging alternative‑pathway niche. In addition, the PDE‑7 inhibitor for cocaine use disorder, fully funded by the National Institute on Drug Abuse, taps a high‑price, high‑public‑health‑impact indication, and the oncology platform (AML lead) has preclinical data indicating broad activity. This diversification creates multiple potential revenue sources, reducing dependence on a single asset.
Omeros has effectively navigated regulatory scrutiny surrounding the use of historical controls. The company disclosed robust real‑world registry data from Kyoto and maintained that the registry meets statistical validity for the pivotal trial. While the FDA has issued information requests in the past, Omeros’s proactive responses and the alignment of the external data with the trial cohort have likely mitigated concerns. The clear regulatory pathway—PDUFA date December 26 and a mid‑2026 EMA decision—provides a predictable timeline for market entry, allowing the company to align commercial plans with reimbursement cycles and to forecast cash flows with greater confidence.
Market dynamics favor Omeros’s complement focus due to the emerging paradigm shift toward precision immunology. The failure of broad C5 inhibition to protect against infection underscores the need for upstream, selective blockade of the lectin pathway, a niche where Omeros’s technology differentiates. As competing modalities (C3 and C5 inhibitors) face safety hurdles and reimbursement challenges, Yartemlia’s superior safety profile and proven survival benefit create a first‑mover advantage that can translate into durable market share and brand recognition, particularly as transplant programs increasingly adopt the drug as a standard of care.

Omeros’s strategic transaction with Novo Nordisk, which delivers an upfront $240 million and up to $2.1 billion in milestones and royalties, dramatically strengthens the company’s balance sheet and provides the working capital needed for a global launch of Yartemlia. This injection of cash, coupled with the debt repayment plan that eliminates the $25 million liquidity covenant, positions Omeros to fund the anticipated launch, scale manufacturing, and accelerate other pipeline programs without the need for additional equity or high‑cost debt. The transaction also signals external validation of Omeros’s science by a pharmaceutical leader, which may ease future licensing or partnership negotiations for other assets, creating additional revenue streams beyond the core complement franchise.
Yartemlia’s first‑in‑class status as the only approved therapy for transplant‑associated thrombotic microangiopathy (TA‑TMA) creates a sizable, underserved market. With up to 56 % of allogeneic transplant recipients at risk, the patient population is large and high‑severity, generating strong pricing leverage at $36 k per vial and an expected 8–10 vial course. The company’s early adoption by transplant centers, the rapid commercial shipments reported in early January, and the supportive payor infrastructure (ICD‑10 code, CPT code, NTAP) suggest a swift reimbursement trajectory and the potential for rapid market penetration, especially in the United States where the therapeutic need is acute.
The company’s pipeline breadth mitigates the risk of overreliance on Yartemlia. Phase II‑ready OMS 1029 offers a once‑quarterly MASP‑2 antibody that could extend the company’s reach into chronic complement indications, while the MASP‑3 small‑molecule program—unrestricted by the Novo deal—provides an alternative route to the emerging alternative‑pathway niche. In addition, the PDE‑7 inhibitor for cocaine use disorder, fully funded by the National Institute on Drug Abuse, taps a high‑price, high‑public‑health‑impact indication, and the oncology platform (AML lead) has preclinical data indicating broad activity. This diversification creates multiple potential revenue sources, reducing dependence on a single asset.
Omeros has effectively navigated regulatory scrutiny surrounding the use of historical controls. The company disclosed robust real‑world registry data from Kyoto and maintained that the registry meets statistical validity for the pivotal trial. While the FDA has issued information requests in the past, Omeros’s proactive responses and the alignment of the external data with the trial cohort have likely mitigated concerns. The clear regulatory pathway—PDUFA date December 26 and a mid‑2026 EMA decision—provides a predictable timeline for market entry, allowing the company to align commercial plans with reimbursement cycles and to forecast cash flows with greater confidence.
Market dynamics favor Omeros’s complement focus due to the emerging paradigm shift toward precision immunology. The failure of broad C5 inhibition to protect against infection underscores the need for upstream, selective blockade of the lectin pathway, a niche where Omeros’s technology differentiates. As competing modalities (C3 and C5 inhibitors) face safety hurdles and reimbursement challenges, Yartemlia’s superior safety profile and proven survival benefit create a first‑mover advantage that can translate into durable market share and brand recognition, particularly as transplant programs increasingly adopt the drug as a standard of care.

Bear case

The company’s cash position, though bolstered by the Novo transaction, remains modest at $36 million plus the anticipated $240 million, and the burn rate of $22 million per quarter indicates that even with the immediate infusion, Omeros will need to rely on milestone and royalty payments that are not guaranteed until later phases of development or sales. The repayment of short‑term debt leaves only a $70.8 million 2029 note, which may be a liquidity constraint if Yartemlia’s launch stalls, if reimbursement delays occur, or if post‑marketing safety signals emerge, potentially jeopardizing cash flow and the ability to fund other pipeline programs.
The regulatory approval of Yartemlia, while a milestone, hinges on complex payer reimbursement dynamics and the availability of the new technology add‑on payment (NTAP). The company’s briefing indicates that the NTAP decision is pending a CMS town hall in December, and any delay or unfavorable outcome would compress the net reimbursement, eroding the anticipated price premium and potentially limiting market penetration. Moreover, the presence of serious infections in 36 % of trial patients raises safety concerns that could prompt additional post‑marketing studies, labeling changes, or stricter monitoring, all of which could delay commercialization or increase operating costs.
The Novo Nordisk deal, although providing significant upfront cash, imposes a near‑exclusive license on the MASP‑3 antibody, effectively limiting Omeros’s ability to develop or commercialize the antibody in other indications. The transaction also requires Omeros to forgo development and commercialization of MASP‑3 antibodies except for small‑molecule inhibitors, potentially ceding a high‑growth market to Novo Nordisk and narrowing the company’s future product pipeline. This strategic trade‑off could reduce long‑term value creation if the MASP‑3 market expands beyond the current scope.
Omeros’s pipeline, while diverse, is still largely at the preclinical or early clinical stage, exposing the company to typical developmental risks. The MASP‑2 antibody OMS 1029, although phase II ready, requires a robust manufacturing scale‑up and regulatory approval that could face unforeseen scientific or safety hurdles. The oncology program’s AML lead candidate, while showing superior preclinical efficacy, is still several years away from clinical entry and could face intense competition from other novel agents, potentially diluting its market potential. These uncertainties could divert resources from Yartemlia commercialization and strain the company’s modest capital base.
Market perception remains cautious, as reflected in the modest share price movements and the fact that the company has historically reported net losses, even after adjusting for non‑cash charges. The heavy reliance on non‑cash mark‑to‑market adjustments creates earnings volatility that could deter investors wary of financial noise. Additionally, the company's communications have been notably cautious regarding pricing strategy and commercial plans, suggesting potential conservatism in revenue forecasting that may not fully capture the true upside, thereby tempering investor enthusiasm and creating valuation pressure.

The company’s cash position, though bolstered by the Novo transaction, remains modest at $36 million plus the anticipated $240 million, and the burn rate of $22 million per quarter indicates that even with the immediate infusion, Omeros will need to rely on milestone and royalty payments that are not guaranteed until later phases of development or sales. The repayment of short‑term debt leaves only a $70.8 million 2029 note, which may be a liquidity constraint if Yartemlia’s launch stalls, if reimbursement delays occur, or if post‑marketing safety signals emerge, potentially jeopardizing cash flow and the ability to fund other pipeline programs.
The regulatory approval of Yartemlia, while a milestone, hinges on complex payer reimbursement dynamics and the availability of the new technology add‑on payment (NTAP). The company’s briefing indicates that the NTAP decision is pending a CMS town hall in December, and any delay or unfavorable outcome would compress the net reimbursement, eroding the anticipated price premium and potentially limiting market penetration. Moreover, the presence of serious infections in 36 % of trial patients raises safety concerns that could prompt additional post‑marketing studies, labeling changes, or stricter monitoring, all of which could delay commercialization or increase operating costs.
The Novo Nordisk deal, although providing significant upfront cash, imposes a near‑exclusive license on the MASP‑3 antibody, effectively limiting Omeros’s ability to develop or commercialize the antibody in other indications. The transaction also requires Omeros to forgo development and commercialization of MASP‑3 antibodies except for small‑molecule inhibitors, potentially ceding a high‑growth market to Novo Nordisk and narrowing the company’s future product pipeline. This strategic trade‑off could reduce long‑term value creation if the MASP‑3 market expands beyond the current scope.
Omeros’s pipeline, while diverse, is still largely at the preclinical or early clinical stage, exposing the company to typical developmental risks. The MASP‑2 antibody OMS 1029, although phase II ready, requires a robust manufacturing scale‑up and regulatory approval that could face unforeseen scientific or safety hurdles. The oncology program’s AML lead candidate, while showing superior preclinical efficacy, is still several years away from clinical entry and could face intense competition from other novel agents, potentially diluting its market potential. These uncertainties could divert resources from Yartemlia commercialization and strain the company’s modest capital base.
Market perception remains cautious, as reflected in the modest share price movements and the fact that the company has historically reported net losses, even after adjusting for non‑cash charges. The heavy reliance on non‑cash mark‑to‑market adjustments creates earnings volatility that could deter investors wary of financial noise. Additionally, the company's communications have been notably cautious regarding pricing strategy and commercial plans, suggesting potential conservatism in revenue forecasting that may not fully capture the true upside, thereby tempering investor enthusiasm and creating valuation pressure.

Customer Breakdown of Revenue (2014)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	1,218,282.90 Bn	0.91	-	-
2	ATHE	Alterity Therapeutics Ltd	881,084.00 Bn	-	-	-
3	NBTX	Nanobiotix S.A.	3,028.69 Bn	-96.32	90,432.83	0.11 Bn
4	LEGN	Legend Biotech Corp	2,867.00 Bn	0.00	2,786.90	0.32 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	114.48 Bn	26.49	9.37	-
6	REGN	Regeneron Pharmaceuticals, Inc.	74.20 Bn	16.76	4.97	1.99 Bn
7	EVAX	Evaxion A/S	64.80 Bn	-5,982.48	8,606.93	-
8	ALNY	Alnylam Pharmaceuticals, Inc.	38.98 Bn	77.39	9.09	-

Research Tools

Omeros Corp (NASDAQ: OMER)

About

Investment thesis

Bull case

Bear case

Customer Breakdown of Revenue (2014)

Peer comparison

Research Tools

Omeros Corp (NASDAQ: OMER)

About

Investment thesis

Bull case

Bear case

Customer Breakdown of Revenue (2014)

Peer comparison

Create an account

Sign In

Reset Password